VSIR and neoplasm: Blocking PD-1H with a specific antagonist mAb can significantly reduce tumor growth in multiple mouse tumor models, including B16 melanoma, MB49 bladder carcinoma, and PTEN/BRAF inducible melanoma by promoting T cell–mediated immunity (12).